Stable Metastatic Breast Cancer During Treatment With a CDK4/6 Inhibitor and Fulvestrant
This breast cancer diagnosis at a glance
- Stage at diagnosis
- Stage IV
- Biomarkers
- Hormone receptor-positive, HER2-negative
- Sex
- Female
- Spread to
- liver
- Treatment
- targeted therapy and endocrine therapy
- Outcome
- Stable Disease
Treatment course, step by step
- Received tiremciclib with fulvestrant for 18 months.
- Continued regular follow-up with stable cancer during treatment.
What happened, in summary
A 60-year-old woman had been diagnosed two years earlier with advanced breast cancer that had spread to the liver. Pathology showed hormone receptor-positive, HER2-negative disease. She was treated with the CDK4/6 inhibitor tiremciclib together with fulvestrant.
After 18 months on the combination, her cancer remained stable on regular follow-up. During treatment, however, she developed persistent eye irritation, light sensitivity, tearing, and characteristic deposits in both corneas. Eye examination led to a diagnosis of vortex keratopathy. She received lubricating eye drops, which slightly improved her symptoms, while the corneal findings remained present.
The cancer remained stable while she continued systemic therapy. Her care also included ongoing eye follow-up for the treatment-related corneal changes, while breast-cancer treatment continued without a documented change in disease status.
Where this story comes from
This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full
How we source and attribute stories Accuracy and limitations
Collections this story belongs to
- Stage 4 Breast Cancer 295 stories
- Hormone Receptor Positive Breast Cancer 41 stories
- Endocrine Therapy for Breast Cancer 36 stories
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer